心力衰竭患者肿瘤坏死因子样凋亡微弱诱导剂的血清表达及意义被引量：1

Expression and Clinical Value of Serum Tumor Necrosis Factor-like Weak Inducer of Apoptosis in Heart Failure

下载PDF

导出

摘要目的:探讨心力衰竭患者血清肿瘤坏死因子样凋亡微弱诱导剂(TWEAK)表达的临床意义。方法:选择103例慢性心力衰竭患者,根据心脏超声结果分为射血分数正常的心衰组(HFNEF组,n=19)与射血分数降低的心衰组(HFREF组,n=84);根据NYHA分级分为心功能Ⅰ、Ⅱ、Ⅲ、Ⅳ级组。选择同期32名健康体检者为对照组。所有被研究者接受心脏超声、血清TWEAK与脑钠肽(BNP)检测,比较各组间各指标的差异。同时比较发病6个月内,两心衰患者组心脑血管事件发生率的差异。结果:与正常对照组比较,两心衰组血清TWEAK水平明显降低,BNP水平明显升高(P<0.05或P<0.01),HFREF组尤为显著(P<0.01)。随着心功能的恶化,血清BNP水平明显升高,血清TWEAK水平显著下降。直线相关分析显示:HFNEF组和HFREF组,血清TWEAK与BNP均呈负相关(r=-0.74,P<0.05;r=-0.85,P<0.05)。随访6个月,HFREF组患者心脑血管事件发生率明显高于HFNEF组患者(P<0.05)。结论:血清TWEAK与血清BNP相关性良好,其可能在心衰的临床诊断、分级中具有重要的应用价值。 Objective: To investigate the changes of serum tumor necrosis factor-like weak inducer of apoptosis (TWEAK) levels in patients with heart failure (HF) and its clinical value. Method: 103 HF patients were enrolled in this study and divided into 2 groups: heart failure with normal left ventricular ejection fraction congestive group group (HFNEF, n=19) and heart failure with reduced left ventricular ejection fraction congestive group (HFREF, n=84) according to the echocardiography. They were also divided into 4 groups: NYHA I, II, III, IV groups according to the cardiac function. 32 healthy people were set as the control group. All patiens were undergone echocardiograph and serum brain natriuretic peptide (BNP) was detected. Serum TWEAK levels were measured by ELISA. Results: Compared with the control group, lower TWEAK and higher BNP levels were occurred in the HFNEF group and HFREF group (P<0.01), especially in the latter; Increased serum TWEAK levels were associated with the severity of cardiac function. Linear correlation analysis showed that the levels of serum TWEAK was negative correlated with serum BNP levels both in HFNEF group and HFREF group (r=-0.74,P<0.05;r=-0.85,P<0.05); 6 months follow-up, higher cardiovascular and cerebrovascular events were occurred in HFREF group than those in HFNEF group (P<0.01). Conclusion: Serum TWEAK levels in patients with heart failure were significantly decreased, especially in patients with HFREF. TWEAK might be an important predictor of heart failure.

作者李伟龙武凌宁

机构地区湖北省咸宁市通城县人民医院内二科湖北省黄石市大冶有色金属公司总医院

出处《微循环学杂志》 2013年第3期37-39,I0002,共4页 Chinese Journal of Microcirculation

关键词心力衰竭肿瘤坏死因子样凋亡微弱诱导剂脑钠肽左室射血分数 Heart failure Tumor necrosis factor-like weak inducer of apoptosis Brain natriuretic peptide Left ventricular ejection fraction

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献14

1Dickstein K,Vardas PE,Auricchio A,et al.2010 focused up-date of ESC Guidelines on device therapy in heart failure:an up-date of the 2008 ESC Guidelines for the diagnosis and treatmentof acute and chronic heart failure and the 2007 ESC Guidelines forcardiac and resynchronization therapy.Developed with the spe'cial contribution of the Heart Failure Association and the Europe-an Heart Rhythm Association[J].Eur J Heart Fail,2010,12(11):1 143-1 153.
2Ikner A,Ashkenazi A.TWEAK induces apoptosis through adeath-signaling complex comprising receptor-interacting protein 1(RIP1),Fas-associated death domain (FADD),and caspase-8[J].J Biol Chem,2011,286(24):21 546-21 554.
3Ren MY,Sui SJ.The role of TWEAK/Fnl4 in cardiac remode-ling[J].Mol Biol Rep,2012,39(11):9 971-9 977.
4Findlay DM,Atkins GJ.TWEAK and TNF regulation ofsclerostin:a novel pathway for the regulation of bone remodel-ling[J].Adv Exp Med Biol,2011,691:337-348.
5无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量：3717
6Jessup M,Abraham WT,Casey DE,et al.2009 focused up-date:ACCF/AHA guidelines for the diagnosis and managementof heart failure in adults:a report of the American College ofCardiology Foundation/American Heart Association Task Forceon Practice Guidelines:developed in collaboration with the inter-national society for heart and lung transplantation[J].Circula-tion,2009,119(14):1 977-2 016.
7戴雯,李艳,苏汉文.标本类型及存放时间对心衰患者BNP和NT-proBNP检测结果的影响[J].微循环学杂志,2010,20(2):37-38. 被引量：18
8Chapman MS,Wu L,Amatucci A,et al.TWEAK signalsthrough JAK-STAT to induce tumor cell apoptosis [J].Cyto-kine,2013,61(1):210-217.
9Izquierdo MC,Sanz AB,Mezzano S,et al.TWEAK (tumornecrosis factor-like weak inducer of apoptosis) activates CXCL16expression during renal tubulointerstitial inflammation[J].Kid-ney Int,2012,81(11):1 098-1 107.
10Richter B,Rychli K,Hohensinner PJ,et al.Differences in thepredictive value of tumor necrosis factor-like weak inducer ofapoptosis (TWEAK) in advanced ischemic and non-ischemicheart failure[J],Atherosclerosis,2010,213(2):545-548.

二级参考文献47

1王方正,张澍,黄德嘉,华伟,孙宝贵,沈法荣,吴书林,王建安,方全,吴立群,王景峰,王冬梅,郭涛,陈新,中华医学会心电生理和起搏分会心脏再同步治疗专家工作组.心脏再同步治疗慢性心力衰竭的建议[J].中华心律失常学杂志,2006,10(2):90-102. 被引量：91
2Tang WH,Francis GS,Morrow DA,et al.National academy of clinical biochemistry laboratory medicine practice guidelines:clinical utilization of cardiac biomarker testing in heart failure.Circulation,2007,116(5):e99-el09.
3Troaghton RW,Frampton CM,Yandte TG,et al.Treatment of heart failure guided by plasma aminotemfina brain natriuretie peptide concentrations.Lancet,2000,355(9210):1 126-1 130.
4Yeo KT,Wu AH,Apple FS,et al.Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay.Clin Chem Acta,2003,338(1-2):107-115.
5Wu AH,Packer M,Smith A,et al.Analytical and clinical evaluation of the bayer ADVIA centaur automated B-Type natriuretic peptide assay in patients with heart failure:a multisite study.Clinical Chemistry,2004,50(5):867-873.
6Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol, 1997, 80(11A) : 15L-25L
7Braunwald E,Bristow MR Congestive heart failure: fifty years of progress. Circulation, 2000, 102(20 Suppl 4) : Ⅳ14-23.
8Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) : developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 2005, 112 (12) :e154-235.
9Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary ( update 2005 ):The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J, 2005, 26(11): 1115-1140.
10Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006 : diagnosis and management. Can J Cardiol, 2006, 22 (1): 23-45.